Forum for Science, Industry and Business

Sponsored by:     3M 
Search our Site:

 

Versatile microRNAs choke off cancer blood supply, suppress metastasis

12.09.2013
Elevated miR-200 boosts survival of lung, ovarian, renal, triple-negative breast cancer patients

A family of microRNAs (miR-200) blocks cancer progression and metastasis by stifling a tumor's ability to weave new blood vessels to support itself, researchers at The University of Texas MD Anderson Cancer Center report today in Nature Communications.

Patients with lung, ovarian, kidney or triple-negative breast cancers live longer if they have high levels of miR-200 expression, the researchers found.

Subsequent experiments showed for the first time that miR-200 hinders new blood vessel development, or angiogenesis, and does so by targeting cytokines interleukin-8 (IL-8) and CXCL1.

"Nanoparticle delivery of miR-200 blocked new blood vessel development, reduced cancer burden and inhibited metastasis in mouse models of all four cancers," said Anil Sood, M.D., professor of Gynecologic Oncology, senior author of the study.

The team's findings highlight the therapeutic potential of nanoparticle-delivered miR-200 and of IL-8 as a possible biomarker for identifying patients who might benefit from treatment. Sood said safety studies will need to be completed before clinical development can begin.

Micro RNAs do not code for genes like their cousins, the messenger RNAs. They regulate gene activation and expression.

"We initially looked at miR-200 because we have an approach for targeting and delivering these molecules with nanoparticles and miR-200 is known to inhibit EMT, a cellular transition associated with cancer progression and metastasis," said Sood, who also holds the Bettyann Asche Murray Distinguished Professorship in Ovarian Cancer Research.

First author Chad Pecot, M.D., a fellow in Cancer Medicine, said initial research provided a new perspective. "Cautionary tales emerged from the literature about poor outcomes in hormone-positive breast cancer, so we decided to delve more deeply into understanding the mechanisms involved."

miR-200 effect differs by breast cancer type

Sood and colleagues analyzed hundreds of annotated ovarian, renal, breast and non-small cell lung cancer samples from The Cancer Genome Atlas for expression of all five miR-200 family members. Low expression of miR-200 was associated with poor survival in lung, ovarian and renal cancers, but improved survival for breast cancer.

However, they found a striking difference when they analyzed breast cancers by those that are hormone-receptor positive (luminal) and those that lack hormone receptors or the HER2 protein, called triple-negative breast cancer. High expression for miR-200 was associated with improved survival for triple-negative disease, which is more difficult to treat due to its lack of therapeutic targets.

Gene expression analysis of ovarian and lung cancer cell lines pointed to an angiogenesis network involving both IL-8 and CXCL1. By mining public miRNA and messenger RNA databases, the researchers found:

An inverse relationship between expression of four of the five members of the miR-200 family and IL-8.

Lung, ovarian, kidney and triple-negative breast cancer all have elevated IL-8 and CXCL1 expression compared to hormone-positive breast cancers.

Elevated IL-8 associated with poor overall survival in lung, ovarian, renal and triple-negative breast cancer cases.

Treating cancer cell lines with miR-200 decreased levels of IL-8 and CXCL1, and the team also identified binding sites for these genes, meaning they are direct miR-200 targets.

Mice treated with miR-200 family members delivered in a fatty nanoparticle developed by Sood and Gabriel Lopez, M.D., professor of Experimental Therapeutics, had steep reductions in lung cancer tumor volume, tumor size and the density of small blood vessels compared to controls. Results were repeated with kidney, ovarian and triple-negative breast cancers.

miR-200 nanoparticles stymie metastasis

In mouse models of lung and triple-negative breast cancers prone to spread to other organs, treatment with the miR-200 nanoliposomes significantly reduced the volume of the primary tumor and the number and size of metastases in other organs compared to controls. Similar results were observed in an ovarian cancer model, accompanied by sharp reductions in IL-8 levels and blood vessel formation.

Additional experiments showed that these therapeutic effects were due to blocking of IL-8 levels by miR-200. In tumors that had high amounts of synthetically produced IL-8 (designed so that miR-200 could not block it) the cancer burden was no longer reduced. Circulating IL-8 levels in the blood strongly correlated with tumor burden, Pecot said, suggesting it may serve as a possible biomarker for miR-200 treatment.

Treatment of blood vessels cuts metastases by 92 percent

The team then used a chitosan nanoparticle – derived from chitin in the shells of crustaceans – to deliver miR-200 straight to blood vessels. Combination delivery of two types of miR-200 reduced ovarian cancer metastases by 92 percent over controls.

Targeting a second ovarian cancer line with the chitosan nanoparticles also developed by Sood and colleagues, resulted in decreased primary and metastatic tumor burden and reduced blood vessel formation with no apparent toxicity observed in treated mice.

Co-authors with Sood, Pecot and Lopez are Rajesha Rupaimoole, Ph.D., Cristina Ivan, Ph.D., Chunhua Lu, Sherry Wu, Hee-Dong Han, Justin Bottsford-Miller, M.D., Behrouz Zand, M.D., Myrthala Moreno-Smith, Ph.D., Lingegowda Mangala, Ph.D., Ph.D., Morgan Taylor, Ph.D., Healther Dalton, Ph.D.,Yunfei Wen, Ph.D., and Yu Kang, M.D., all of the Gynecologic Oncology; Da Yang, Ph.D., Yuexin Liu, Ph.D., and Wei Zhang, Ph.D., of Pathology; Rehan Akbani, Ph.D., Anna Unruh, and Keith Baggerly, Ph.D., of Bioinformatics and Computational Biology; Maitri Shah, Cristian Rodriguez-Villasana, Ph.D., Vianey Gonzalez-Villasana, Ph.D., and George Calin, M.D., Ph.D., of Experimental Therapeutics; Sang Bae Kim, Vasudha Sehgal, Ph.D., Ju-Seog Lee, Ph.D., Prahlad Ram, Ph.D., and Ana-Maria Gonzalez-Angulo, M.D., of Breast Medical Oncology; Murali Ravoori and Vikas Kundra, M.D., Ph.D., of Experimental Diagnostic Imaging; Li Huang and Xinna Zhang of Cancer Biology; Rouba Ali-Fehmi, M.D., of Wayne State University School of Medicine, Karmanos Cancer Institute, Detroit; and Pierre Massion, M.D., of Vanderbilt Ingram Cancer Center, Vanderbilt University, Nashville, Tenn.

Sood, Lopez, Xinna Zhang, Wei Zhang, Calin, Mangala and Ivan are also with MD Anderson's Center for RNA Interference and Non-Coding RNA. Sang Bae Kim and Anna Unruh are students in The University of Texas Graduate School of Biomedical Sciences, a joint operation of MD Anderson and The University of Texas Health Science Center at Houston.

This research was funded by grants from the National Cancer Institute of the National Institutes of Health (CA109298, P50 CA083639, P50 CA098258, CA128797, RC2GM092599, U54 CA151668 and

U24CA143835, CA009666, CA90949, CA143883, T32 CA101642, and U24CA143835); the Cancer Prevention and Research Institute of Texas, the Ovarian Cancer Research Fund, Inc., The U.S. Department of Defense, The Marcus Foundation, Inc., Laura Lee Blanton Ovarian Cancer Endowed Fund, the Vanderbilt SPORE in lung cancer ; the 2011 Conquer Cancer Foundation ASCO Young Investigator Award, MD Anderson's Division of Cancer Medicine Advanced Scholar Program, The Cancer Genome Atlas MD Anderson Data Analysis Center, an MD Anderson Odyssey Fellowship, Diane Denson Tobola Fellowship for Ovarian Cancer Research and the Harold C. and Mary L. Dailey Endowment Fellowships.

Scott Merville | EurekAlert!
Further information:
http://www.mdanderson.org

More articles from Life Sciences:

nachricht An evolutionary heads-up – The brain size advantage
22.05.2015 | Veterinärmedizinische Universität Wien

nachricht Endocrine disrupting chemicals in baby teethers
21.05.2015 | Goethe-Universität Frankfurt am Main

All articles from Life Sciences >>>

The most recent press releases about innovation >>>

Die letzten 5 Focus-News des innovations-reports im Überblick:

Im Focus: Basel Physicists Develop Efficient Method of Signal Transmission from Nanocomponents

Physicists have developed an innovative method that could enable the efficient use of nanocomponents in electronic circuits. To achieve this, they have developed a layout in which a nanocomponent is connected to two electrical conductors, which uncouple the electrical signal in a highly efficient manner. The scientists at the Department of Physics and the Swiss Nanoscience Institute at the University of Basel have published their results in the scientific journal “Nature Communications” together with their colleagues from ETH Zurich.

Electronic components are becoming smaller and smaller. Components measuring just a few nanometers – the size of around ten atoms – are already being produced...

Im Focus: IoT-based Advanced Automobile Parking Navigation System

Development and implementation of an advanced automobile parking navigation platform for parking services

To fulfill the requirements of the industry, PolyU researchers developed the Advanced Automobile Parking Navigation Platform, which includes smart devices,...

Im Focus: First electrical car ferry in the world in operation in Norway now

  • Siemens delivers electric propulsion system and charging stations with lithium-ion batteries charged from hydro power
  • Ferry only uses 150 kilowatt hours (kWh) per route and reduces cost of fuel by 60 percent
  • Milestone on the road to operating emission-free ferries

The world's first electrical car and passenger ferry powered by batteries has entered service in Norway. The ferry only uses 150 kWh per route, which...

Im Focus: Into the ice – RV Polarstern opens the arctic season by setting course for Spitsbergen

On Tuesday, 19 May 2015 the research icebreaker Polarstern will leave its home port in Bremerhaven, setting a course for the Arctic. Led by Dr Ilka Peeken from the Alfred Wegener Institute, Helmholtz Centre for Polar and Marine Research (AWI) a team of 53 researchers from 11 countries will investigate the effects of climate change in the Arctic, from the surface ice floes down to the seafloor.

RV Polarstern will enter the sea-ice zone north of Spitsbergen. Covering two shallow regions on their way to deeper waters, the scientists on board will focus...

Im Focus: Gel filled with nanosponges cleans up MRSA infections

Nanoengineers at the University of California, San Diego developed a gel filled with toxin-absorbing nanosponges that could lead to an effective treatment for skin and wound infections caused by MRSA (methicillin-resistant Staphylococcus aureus), an antibiotic-resistant bacteria. This "nanosponge-hydrogel" minimized the growth of skin lesions on mice infected with MRSA - without the use of antibiotics. The researchers recently published their findings online in Advanced Materials.

To make the nanosponge-hydrogel, the team mixed nanosponges, which are nanoparticles that absorb dangerous toxins produced by MRSA, E. coli and other...

All Focus news of the innovation-report >>>

Anzeige

Anzeige

Event News

International symposium: trends in spatial analysis and modelling for a more sustainable land use

20.05.2015 | Event News

15th conference of the International Association of Colloid and Interface Scientists

18.05.2015 | Event News

EHFG 2015: Securing health in Europe. Balancing priorities, sharing responsibilities

12.05.2015 | Event News

 
Latest News

Mesoporous Particles for the Development of Drug Delivery System Safe to Human Bodies

22.05.2015 | Materials Sciences

Computing at the Speed of Light

22.05.2015 | Information Technology

Development of Gold Nanoparticles That Control Osteogenic Differentiation of Stem Cells

22.05.2015 | Materials Sciences

VideoLinks
B2B-VideoLinks
More VideoLinks >>>